Cervical Cancer Screening: What the Tests Check and When to Have Them

Cervical cancer screening is a routine test that looks for a high-risk virus and early cell changes on the cervix so that problems can be treated long before they could ever become cancer. It is one of the few screening programmes that can prevent a cancer rather than only find it early.

Almost every case of cervical cancer is caused by long-lasting infection with high-risk types of human papillomavirus (HPV), a common virus passed on through skin and genital contact ¹. Most HPV infections clear on their own within a year or two. Screening exists to catch the small share that linger and start to change cervical cells.

Key Takeaways

• Screening checks for high-risk HPV and abnormal cells, aiming to act before cancer forms.
• Typical programmes start at age 25 to 30 and run to about age 65.
• HPV testing every 5 years is the preferred primary method in many countries.
• An abnormal result is common and usually leads to monitoring or colposcopy, not a diagnosis.

What Screening Actually Tests For

Screening targets two things: the cause and the early effect. The HPV test looks for the genetic material of high-risk HPV types in cells taken from the cervix. The cytology test, often called a Pap test, examines those same cells under a microscope for shape and structure changes. Because persistent high-risk HPV is the necessary cause of nearly all cervical cancer, finding it early flags who needs closer attention ¹.

The World Health Organization now recommends HPV DNA testing as the preferred primary screening method, replacing cytology-first approaches where resources allow ². The sample is collected the same way regardless of which test the laboratory runs, so the experience in the room feels identical.

When to Start and How Often

Most national programmes begin screening between ages 25 and 30 and continue to around age 65, then stop for people with a recent history of normal results ³. Starting in the mid-twenties rather than the teens reflects how common and how often harmless HPV is in younger people, where treating transient changes would do more harm than good.

Interval depends on the test. With primary HPV testing, a negative result usually means a 5 year gap before the next screen, because a clear HPV result is strongly reassuring ². Cytology used on its own is typically repeated every 3 years, since it is less sensitive at a single visit. The WHO target is for women to be screened at least twice in their lifetime, at ages 35 and 45, as a minimum in settings with limited resources ³.

HPV Testing Versus Cytology

HPV testing detects more pre-cancer earlier than cytology and gives longer protection between screens. A Cochrane review comparing the two found that HPV testing detects more high-grade cervical changes than cytology and allows safe extension of screening intervals ⁴. Its trade-off is that it picks up infections that would have cleared anyway, which is why a positive HPV result is followed by a second step rather than immediate treatment.

Cytology remains useful as a triage test: when HPV is positive, the same sample can often be examined for cell changes to decide who needs referral now and who can be rechecked in a year. Some programmes also offer self-sampling, where you collect the swab yourself, which improves participation among people who avoid clinic-based tests.

What Your Results Mean

A negative result is the common outcome and means you return to routine screening. A positive HPV result without cell changes usually leads to a repeat test in 12 months, because many infections clear in that time ². A positive result with abnormal cells, or persistent HPV, leads to colposcopy, a clinic examination that uses a magnifying device to inspect the cervix closely and take a small biopsy if needed.

It helps to know the scale of the system before your first visit. In a busy clinic the result letter can read alarmingly, with terms like “low-grade” or “high-grade” changes. High-grade changes are pre-cancer, not cancer, and are usually removed in a short outpatient procedure with high cure rates. The point of the whole programme is to find changes at this treatable stage.

Screening and the HPV Vaccine

Vaccination and screening are partners, not alternatives. The HPV vaccine prevents infection with the types that cause most cervical cancers, and screening catches the cases the vaccine does not cover ³. WHO has set a global goal of eliminating cervical cancer as a public health problem, built on vaccinating 90 percent of girls, screening 70 percent of women twice by age 45, and treating 90 percent of those who need it ³. Vaccinated people still follow the normal screening schedule, because no vaccine covers every high-risk type.

This is general information and not medical advice. Talk to a qualified clinician about your own screening schedule, results, and any symptoms.